LC–MS/MS methods for determination of venetoclax in human plasma and cerebrospinal fluid
Biomedical Chromatography · 2023
DOI: 10.1002/bmc.5738 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2023. Verfasst von Yan-Ling Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Sulfonamides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: Outstanding Young and Middle-Aged Talents Support Program of the First Affiliated Hospital of Nanjing Medical University, Establishment of Molecularly Targeted Drug Adverse Reactions Based on Artificial Intelligence Technology.
Abstract (Originalsprache)
We developed and validated sensitive MS/MS methods for the determination of venetoclax, an oral selective B‐cell lymphoma‐2 inhibitor, in human plasma and cerebrospinal fluid (CSF). Acetonitrile was used as protein precipitant. The mobile phase was 10 mM ammonium formate consisting of 0.1% formic acid and acetonitrile (40:60, v/v). The analytes were separated on an ACQUITY UPLC HSS T3 column (2.1 × 50 mm, 1.8 μm) in 5 min. An API 4000 mass spectrometer was selected to quantify venetoclax and internal standard using m / z 868.3 → 636.3 and 876.3 → 644.3 under multiple response monitoring mode. In plasma, the calibration curve exhibited good linearity ranging from 20.0 to 5000 ng/mL, whereas in the CSF, the linear range was 0.500–100 ng/mL. The matrix effect of venetoclax and internal standard (venetoclax‐d8) was not obvious in both plasma and CSF. The inter‐ and intra‐run accuracy was within ±11.9%, and the inter‐ and intra‐run precision was below 13.6%. Both methods had no carryover, and the recovery was close to 100%. The validated methods were employed to quantify the concentrations of venetoclax in the plasma and CSF of patients diagnosed with chronic lymphocytic leukemia or acute myelogenous leukemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- School of Pharmacy, Nanjing Medical University, Nanjing, China.
ORCID-Profile: Yong-Qing Wang
Förderung
- Outstanding Young and Middle-Aged Talents Support Program of the First Affiliated Hospital of Nanjing Medical University
- Establishment of Molecularly Targeted Drug Adverse Reactions Based on Artificial Intelligence Technology
Zitieren
APA
Yang, Y. L., Qian, Z. Y., Zhao, Y., Chen, X. L., Huang, Q. Y., Guo, Y. J., Sun, L. N., & Wang, Y. Q. (2023). LC–MS/MS methods for determination of venetoclax in human plasma and cerebrospinal fluid. Biomedical Chromatography. https://doi.org/10.1002/bmc.5738
Vancouver
Yang YL, Qian ZY, Zhao Y, Chen XL, Huang QY, Guo YJ, et al. LC–MS/MS methods for determination of venetoclax in human plasma and cerebrospinal fluid. Biomedical Chromatography. 2023. doi:10.1002/bmc.5738
BibTeX
@article{Yang2023,
author = {Yang, Yan-Ling and Qian, Zhou-Yi and Zhao, Yang and Chen, Xiang-Long and Huang, Qiong-Ye and Guo, Yu-Jiao and Sun, Lu-Ning and Wang, Yong-Qing},
title = {LC–MS/MS methods for determination of venetoclax in human plasma and cerebrospinal fluid},
journal = {Biomedical Chromatography},
year = {2023},
doi = {10.1002/bmc.5738}
}
EUVIMED